SharpyZepbound for Sleep Apnea: Approval, AHI Results, Coverage
Zepbound (tirzepatide) is FDA-approved, since December 20, 2024, to treat moderate to severe obstructive sleep apnea in adults with obesity, along with diet and exercise. In the SURMOUNT-OSA trials, people on Zepbound had about 25 to 29 fewer breathing events per hour after one year, versus about 5 fewer on placebo. Insurance and Medicare usually want a sleep study and proof of obesity, and CPAP is still the standard treatment, so plan it with your sleep doctor and protect your muscle as the weight comes off with Sharpy.
Can Zepbound treat sleep apnea, and will your insurance pay for it? Yes, Zepbound (tirzepatide) is FDA-approved for moderate to severe obstructive sleep apnea (OSA) in adults with obesity. The approval came on December 20, 2024. In two one-year trials, people on Zepbound had about 20 to 24 fewer breathing pauses per hour than people on placebo. Coverage usually needs a sleep study and a prior authorization.
Sleep apnea and GLP-1 drugs keep showing up in the news. A September 2026 review in JAMA Otolaryngology suggested doctors consider GLP-1 drugs, especially tirzepatide, as an add-on for obesity-related sleep apnea, with CPAP still the main treatment. This guide explains the approval, the trial numbers and the coverage rules in plain English.
Zepbound sleep apnea FDA approval: what it says
Here is what the approval covers, in simple terms:
- Who: adults with obesity who have moderate to severe obstructive sleep apnea
- What: Zepbound, a once-weekly shot made by Eli Lilly
- How: along with a reduced-calorie diet and more physical activity
- Why it mattered: the FDA called it the first drug treatment option for certain people with OSA
Mounjaro has the same medicine inside, but Mounjaro is approved for type 2 diabetes. The sleep apnea approval is on the Zepbound label. Our Zepbound vs Mounjaro guide explains the two brands.
What is AHI, and what counts as moderate to severe?
Sleep doctors grade sleep apnea with the apnea-hypopnea index (AHI). It counts how many times per hour your breathing stops or gets very shallow while you sleep.
| AHI (events per hour) | Usual grade |
|---|---|
| Under 5 | Normal |
| 5 to 14 | Mild |
| 15 to 29 | Moderate |
| 30 or more | Severe |
People in the Zepbound trials started with an average AHI of about 50. That is well into the severe range.
Zepbound sleep apnea study: SURMOUNT-OSA results
Lilly tested Zepbound in two phase 3 trials called SURMOUNT-OSA, published in the New England Journal of Medicine in 2024. The FDA says 469 adults without type 2 diabetes took part. Trial 1 enrolled people who were not using a CPAP or other positive airway pressure (PAP) machine. Trial 2 enrolled people who were using one. Everyone got either the highest dose they could tolerate (10 mg or 15 mg) or a placebo shot for 52 weeks.
| Result at 52 weeks | Trial 1 (no PAP) | Trial 2 (using PAP) |
|---|---|---|
| Starting AHI (average) | 51.5 | 49.5 |
| AHI change on Zepbound | -25.3 events/hour | -29.3 events/hour |
| AHI change on placebo | -5.3 events/hour | -5.5 events/hour |
| Difference vs placebo | -20.0 events/hour | -23.8 events/hour |
| AHI change, % (if everyone stayed on the drug) | -55.0% vs -5.0% | -62.8% vs -6.4% |
| Body weight change (if everyone stayed on the drug) | -18.1% vs -1.3% | -20.1% vs -2.3% |
Sources: NEJM abstract for the events per hour, Lilly's June 2024 announcement for the percentages.
Zepbound also lowered blood pressure, a marker of inflammation (hsCRP) and a measure of low oxygen during sleep. People reported better sleep. More people on Zepbound reached remission or mild OSA than on placebo, but not everyone did.
How does Zepbound help sleep apnea?
Obstructive sleep apnea happens when soft tissue in the throat collapses during sleep and blocks air. Extra fat in the neck, tongue and belly makes that collapse more likely. The FDA says the improvement with Zepbound is likely related to weight loss. So the drug works slowly, as the pounds come off, and not on the first night.
That has a practical meaning. The weight you lose is what helps your airway. But fast weight loss can also take muscle with it. Muscle keeps you strong and helps you keep the weight off later. This is where Sharpy fits: it gives you one daily protein target, one 20-minute strength workout and a Shape Score, so the weight you lose is mostly fat. For the numbers, see our protein target on GLP-1 guide.
Do you still need CPAP on Zepbound?
Probably, at least at first. CPAP works from the first night by holding your airway open with air pressure. Zepbound takes months. In trial 2, people kept using PAP and Zepbound still lowered their AHI further.
Do not stop or change your CPAP on your own. Ask your sleep doctor if a repeat sleep study makes sense after you have lost a good amount of weight. Some people may need lower pressure, and some may not need the machine anymore. Only a test can tell.
Our GLP-1 and sleep guide covers sleep habits that help while you are on these drugs.
Zepbound sleep apnea insurance coverage and criteria
Many plans that refuse to pay for weight-loss drugs will consider Zepbound when the reason is sleep apnea, because it is a treatment for a medical condition. Expect prior authorization. Plans commonly ask for:
- A recent sleep study (in a lab or at home) showing moderate to severe OSA
- Your BMI, showing obesity
- Notes that you are following a diet and activity plan
- Sometimes, notes about CPAP use or why you cannot use it
These are common patterns, not rules every plan follows. Ask your insurer for its written criteria. If you are denied, your doctor can file an appeal with the sleep study attached. Our GLP-1 cost and insurance coverage guide walks through appeals step by step.
Zepbound sleep apnea Medicare coverage
Medicare drug plans usually do not cover drugs used only for weight loss. Sleep apnea is different. CMS has confirmed that Part D plans can cover Zepbound for OSA. Each plan still decides its own rules, so call your plan or check its formulary.
There is also a newer route. The Medicare GLP-1 Bridge runs from July 1, 2026 to December 31, 2027. Eligible Part D members pay $50 a month for certain GLP-1 drugs, and the Zepbound KwikPen is on the list (vials and single-dose pens are not). It is meant for people who do not already have GLP-1 coverage through Medicare, and it has its own BMI rules. Check Medicare.gov/glp1bridge or call 1-800-MEDICARE for your situation.
Side effects to know about
The most common side effects in the trials were stomach-related and mostly mild to moderate. The Zepbound label lists nausea, diarrhea, vomiting, constipation, belly pain, injection site reactions, tiredness, burping, hair loss and heartburn.
The label also has a boxed warning about thyroid C-cell tumors seen in rats. Zepbound should not be used by people with a personal or family history of medullary thyroid cancer or MEN 2. Other warnings include pancreatitis, gallbladder problems and kidney injury from dehydration. Tell your doctor about any surgery, since Zepbound slows the stomach. If you are pregnant, planning to be, or under 18, talk with your doctor first.
Wegovy vs Zepbound for sleep apnea
Both drugs cause weight loss, and weight loss usually helps sleep apnea. But only Zepbound has an FDA approval for OSA. The US Wegovy label does not list sleep apnea as an approved use. That matters for insurance, because plans look for the labeled product. If you have OSA and obesity, ask your doctor which drug fits your plan and your health.
Make the weight loss count
Zepbound can make your sleep apnea less severe because it helps you lose weight. Your job is to make sure that weight comes from fat. Eat protein at every meal, lift something two or three times a week, and track your trend instead of daily swings. If strength training is new, start with our beginner strength program for GLP-1. Sharpy puts your protein target, your 20-minute workout and your Shape Score on one screen, so you can see the change every day.
Bottom line
Zepbound is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity. In SURMOUNT-OSA it cut breathing events by about 20 to 24 per hour more than placebo after a year. Coverage usually needs a sleep study and prior authorization, and Medicare plans may cover it for OSA. Keep your CPAP until your sleep doctor says otherwise, and protect your muscle while you lose.
Sources
- FDA approves first medication for obstructive sleep apnea, FDA, December 20, 2024
- Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205
- Tirzepatide reduced sleep apnea severity by up to nearly two-thirds, Eli Lilly, June 21, 2024
- Zepbound (tirzepatide) prescribing information, DailyMed
- Medicare can now cover Eli Lilly's Zepbound for sleep apnea, CMS says, CNBC via NBC San Diego
- Medicare GLP-1 Bridge, CMS
- Medicare launches $50 GLP-1 Bridge for eligible Part D beneficiaries, Healthcare Finance News
Questions people ask
Is Zepbound FDA approved for sleep apnea?
Yes. On December 20, 2024, the FDA approved Zepbound (tirzepatide) to treat moderate to severe obstructive sleep apnea in adults with obesity. It is used with a reduced-calorie diet and more physical activity. The FDA called it the first drug treatment option for certain people with obstructive sleep apnea.
How does Zepbound help sleep apnea?
Mostly through weight loss. Extra fat around the neck, tongue and belly makes the airway easier to collapse during sleep. The FDA says the drop in breathing events seen with Zepbound is likely related to the weight people lost. Zepbound does not hold the airway open the way a CPAP machine does.
Can Zepbound cure sleep apnea?
Not reliably. In the trials, more people on Zepbound reached remission or mild sleep apnea than on placebo, but many still had sleep apnea after a year. Think of it as a treatment that can lower severity, not a guaranteed cure. Only a repeat sleep study can show where you stand.
Does insurance cover Zepbound for sleep apnea?
Many commercial plans do, usually with prior authorization. Plans commonly ask for a sleep study showing moderate to severe obstructive sleep apnea and a BMI in the obesity range. Each plan sets its own rules, so ask your insurer for the written criteria before you apply.
Does Medicare cover Zepbound for sleep apnea?
Medicare Part D plans are allowed to cover Zepbound for sleep apnea because it is a medical use, not weight loss alone. Coverage still depends on your plan and its prior authorization rules. Separately, the Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers certain GLP-1 drugs, including the Zepbound KwikPen, for $50 a month to eligible people who do not already have coverage.
Do I still need my CPAP on Zepbound?
Do not stop CPAP on your own. One of the two trials enrolled people who kept using CPAP, and Zepbound worked on top of it. Your sleep doctor can decide if and when a new sleep study makes sense to recheck your settings or your need for the machine.
Is Wegovy approved for sleep apnea?
No. As of October 2026, the US Wegovy label covers weight management, lowering heart risk in people with heart disease, and a liver condition called MASH, but not sleep apnea. Zepbound is the GLP-1 medicine with an FDA sleep apnea approval.